Tumor-to–normal organ ratios for pretargeted 1F5-SA (anti-CD20) and BC8-SA (anti-CD45) at 24, 48, 96, and 144 hours after the injection of 1.4 nmol 1F5-SA or BC8-SA
| Organ . | . | Time, h . | |||
|---|---|---|---|---|---|
| 24 . | 48 . | 96 . | 144 . | ||
| Blood | BC8 | 7.8 ± 1.4 | 9.6 ± 2.2 | 12.7 ± 2.8 | 10.3 ± 2.1 |
| 1F5 | 1.8 ± 0.8 | 1.7 ± 1.4 | 1.8 ± 0.5 | 1.7 ± 0.7 | |
| Kidney | BC8 | 9.9 ± 1.2 | 10.5 ± 2.5 | 12.7 ± 3.3 | 19.4 ± 2.6 |
| 1F5 | 3.2 ± 1.5 | 4.1 ± 2.0 | 3.2 ± 2.3 | 4.2 ± 1.4 | |
| Liver | BC8 | 16.4 ± 2.1 | 16.2 ± 3.0 | 10 ± 3.2 | 11.6 ± 2.1 |
| 1F5 | 2.8 ± 0.8 | 3.3 ± 1.6 | 3.8 ± 2.5 | 1.7 ± 0.5 | |
| Lung | BC8 | 16.8 ± 2.3 | 14.2 ± 2.8 | 9.5 ± 3.4 | 9.1 ± 2.1 |
| 1F5 | 4.4 ± 1.3 | 3.7 ± 1.9 | 2.6 ± 2.2 | 1.8 ± 0.7 | |
| Muscle | BC8 | 82 ± 4.6 | 42 ± 4.7 | 47.5 ± 4.9 | 64 ± 2.8 |
| 1F5 | 11.7 ± 1.8 | 6.6 ± 2.8 | 7.0 ± 3.5 | 5.5 ± 1.5 | |
| Small intestine | BC8 | 43.9 ± 3.3 | 31.8 ± 4.2 | 38 ± 4.4 | 17.8 ± 2.9 |
| 1F5 | 15 ± 2.5 | 16.5 ± 3.0 | 8.4 ± 3.6 | 4.6 ± 1.3 | |
| Colon | BC8 | 42.4 ± 4.8 | 19.4 ± 4.7 | 29.7 ± 3.2 | 20.6 ± 2.6 |
| 1F5 | 11.4 ± 2.0 | 8.3 ± 1.1 | 5.7 ± 2.1 | 4.4 ± 1.2 | |
| Spleen | BC8 | 34.2 ± 3.1 | 35 ± 4.5 | 38 ± 4.2 | 22.9 ± 3.1 |
| 1F5 | 11.2 ± 2.6 | 10 ± 2.4 | 7.8 ± 1.9 | 6.1 ± 2.0 | |
| Stomach | BC8 | 31.5 ± 2.4 | 15 ± 3.6 | 31.6 ± 3.2 | 24.6 ± 2.1 |
| 1F5 | 6.9 ± 2.6 | 5.5 ± 1.3 | 5.3 ± 2.0 | 3.5 ± 1.3 | |
| Marrow | BC8 | 14.3 ± 1.8 | 11.7 ± 2.5 | 13.2 ± 1.6 | 10 ± 1.1 |
| 1F5 | 4.5 ± 1.5 | 3.7 ± 1.4 | 3.0 ± 1.8 | 2.0 ± 0.6 | |
| Organ . | . | Time, h . | |||
|---|---|---|---|---|---|
| 24 . | 48 . | 96 . | 144 . | ||
| Blood | BC8 | 7.8 ± 1.4 | 9.6 ± 2.2 | 12.7 ± 2.8 | 10.3 ± 2.1 |
| 1F5 | 1.8 ± 0.8 | 1.7 ± 1.4 | 1.8 ± 0.5 | 1.7 ± 0.7 | |
| Kidney | BC8 | 9.9 ± 1.2 | 10.5 ± 2.5 | 12.7 ± 3.3 | 19.4 ± 2.6 |
| 1F5 | 3.2 ± 1.5 | 4.1 ± 2.0 | 3.2 ± 2.3 | 4.2 ± 1.4 | |
| Liver | BC8 | 16.4 ± 2.1 | 16.2 ± 3.0 | 10 ± 3.2 | 11.6 ± 2.1 |
| 1F5 | 2.8 ± 0.8 | 3.3 ± 1.6 | 3.8 ± 2.5 | 1.7 ± 0.5 | |
| Lung | BC8 | 16.8 ± 2.3 | 14.2 ± 2.8 | 9.5 ± 3.4 | 9.1 ± 2.1 |
| 1F5 | 4.4 ± 1.3 | 3.7 ± 1.9 | 2.6 ± 2.2 | 1.8 ± 0.7 | |
| Muscle | BC8 | 82 ± 4.6 | 42 ± 4.7 | 47.5 ± 4.9 | 64 ± 2.8 |
| 1F5 | 11.7 ± 1.8 | 6.6 ± 2.8 | 7.0 ± 3.5 | 5.5 ± 1.5 | |
| Small intestine | BC8 | 43.9 ± 3.3 | 31.8 ± 4.2 | 38 ± 4.4 | 17.8 ± 2.9 |
| 1F5 | 15 ± 2.5 | 16.5 ± 3.0 | 8.4 ± 3.6 | 4.6 ± 1.3 | |
| Colon | BC8 | 42.4 ± 4.8 | 19.4 ± 4.7 | 29.7 ± 3.2 | 20.6 ± 2.6 |
| 1F5 | 11.4 ± 2.0 | 8.3 ± 1.1 | 5.7 ± 2.1 | 4.4 ± 1.2 | |
| Spleen | BC8 | 34.2 ± 3.1 | 35 ± 4.5 | 38 ± 4.2 | 22.9 ± 3.1 |
| 1F5 | 11.2 ± 2.6 | 10 ± 2.4 | 7.8 ± 1.9 | 6.1 ± 2.0 | |
| Stomach | BC8 | 31.5 ± 2.4 | 15 ± 3.6 | 31.6 ± 3.2 | 24.6 ± 2.1 |
| 1F5 | 6.9 ± 2.6 | 5.5 ± 1.3 | 5.3 ± 2.0 | 3.5 ± 1.3 | |
| Marrow | BC8 | 14.3 ± 1.8 | 11.7 ± 2.5 | 13.2 ± 1.6 | 10 ± 1.1 |
| 1F5 | 4.5 ± 1.5 | 3.7 ± 1.4 | 3.0 ± 1.8 | 2.0 ± 0.6 | |
Clearing agent (5.8 nmol) was delivered at 19 hours after antibody-conjugate administration, followed 2 hours later by111In-biotin (50 μCi [1.85 MBq], 1.2 nmol). Groups of 5 mice/group were used to generate mean values. Data were normalized for tissue weight and corrected for radioactive decay.